A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

September 27, 2023

Study Completion Date

September 27, 2023

Conditions
Schizophrenia
Interventions
DRUG

SEP-363856

SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.

DRUG

Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)

PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.

Trial Locations (7)

33016

Galiz Research, Hialeah

33334

Research Centers of America, Oakland Park

72211

Woodland International Research Group, Little Rock

72758

Woodland Research Northwest, LLC, Rogers

75080

Pillar Clinical Research LLC, Richardson

90806

Collaborative Neuroscience Research, LLC, Long Beach

92102

CNRI - San Diego, LLC, San Diego

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY